Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + albumin-bound paclitaxel
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Camrelizumab + albumin-bound paclitaxel is a combination therapy that pairs a PD-1 inhibitor (camrelizumab) with a chemotherapeutic agent (albumin-bound paclitaxel, also known as nab-paclitaxel). This combination leverages potential synergistic effects between immunotherapy and chemotherapy. Albumin-bound paclitaxel can enhance the efficacy of PD-1 inhibitors by inducing immunogenic cell death and regulating various immune functions. Camrelizumab specifically binds to PD-1 and blocks the interaction between PD-1 and its ligand (PD-L1), allowing T cells to recover immune responses against tumors.
- Brand names
- None (no unique brand name for the combination; individual components have brand names such as Abraxane for albumin-bound paclitaxel)
- Other names
- nab-paclitaxel + camrelizumabalbumin paclitaxel + camrelizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on camrelizumab + albumin-bound paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + albumin-bound paclitaxel.